MedTrace Logo

Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer

NCT04732520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-07-19

No results posted yet for this study

Summary

A prospective, two-arm, non-randomized, concurrently controlled, multi-center, open-label, treat and resect study following patients to 1 year. The study is designed to evaluate the safety and feasibility of the Aliya System for the ablation of solid tumors using pulsed electric field (PEF) energy delivery. The study is intended for adult patients with suspected or confirmed NSCLC 8th ed. Stage IA2, IA3 or IB (\>1 to ≤4 cm solitary lesion) who are surgical candidates and have not received treatment for the index tumor in the last two years.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DEVICE

Pulsed electric field treatment using the Aliya System

pulsed electric field treatment of a single NSCLC tumor

Sponsors & Collaborators

  • Galvanize Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2023-02-13
Completion
2024-02-13
FDA Device
Yes

Countries

  • Hong Kong
  • Netherlands
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04732520 on ClinicalTrials.gov